The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder
Open accessAbstract
The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD). We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions. Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters. In microdialysis studies, atomoxetine increased extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but did not alter 5-HT(EX) levels. Atomoxetine also increased DA(EX) concentrations in PFC 3-fold, but did not alter DA(EX) in striatum or nucleus accumbens. In contrast, the psychostimulant methylphenidate, which is used in ADHD therapy, increased NE(EX) and DA(EX) equally in PFC, but also increased DA(EX) in the striatum and nucleus accumbens to the same level. The expression of the neuronal activity marker Fos was increased 3.7-fold in PFC by atomoxetine administration, but was not increased in the striatum or nucleus accumbens, consistent with the regional distribution of increased DA(EX). We hypothesize that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomoxetine in ADHD. In contrast to methylphenidate, atomoxetine did not increase DA in striatum or nucleus accumbens, suggesting it would not have motoric or drug abuse liabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The precise mechanism by which atomoxetine produces its therapeutic effects in ADHD is unknown, but it is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies [24].”
From Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study (2014) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like methylphenidate, atomoxetine also blocks the NE transporter (Figure 2E), and as the NE transporter clears both NE and DA in the PFC, this increases extracellular levels of both catecholamines (90).”
From Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks (2011) · cites this paper as [90]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, as the NE transporter clears both NE and DA in the PFC, atomoxetine increases both DA and NE in the rat PFC (Bymaster et al., 2002).”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Bymaster et al., 2002
The cited source says what the claim attributes to it.
In the citing paper
“Atomoxetine increases extracellular availability of both NE and DA in the rat PFC (Bymaster et al., 2002).”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Bymaster et al., 2002
The cited source says what the claim attributes to it.
In the citing paper
“The stimulant medications and atomoxetine appear to enhance PFC function by indirectly increasing these catecholamine actions through blockade of norepinephrine and/or dopamine transporters.”
From Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks (2011) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mannuzza, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820190067007 · Cited by 1,368
Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder
Castellanos, F. X. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830070053009 · Cited by 1,183 · cited 1×
“The inhibition constant (K i ) values were calculated from IC 50 and K d values according to the method of Cheng and Prusoff (1973).”
MethodHyperactive Boys Almost Grown Up: I. Psychiatric Status
Gittelman, R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330017002 · Cited by 977
Kuczenski, R., & Segal, D. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052032.x · Cited by 623 · cited 2×
“However, methylphenidate, unlike atomoxetine, also increased DAEX in nucleus accumbens which may mediate the methylphenidate-induced increases in locomotor activity and may also be involved in the rewarding aspects of the drug (Kuczenski and Segal 1997, 1999).”
BackgroundDresel, S., Krause, J., Krause, K.-H., LaFougere, C., Brinkbäumer, K., Kung, H. F., Hahn, K., & Tatsch, K. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000330 · Cited by 278
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1147 · Cited by 228
Electrical Stimulation of the Medial Prefrontal Cortex Increases Dopamine Release in the Striatum
Taber, M. T., & Fibiger, H. C. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.63 · Cited by 99
Research works printed but not linked: 4
- Barkley RA (1977): A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18: 137-165
- Greenhill L (1995): Attention-deficit/hyperactivity disorder: the stimulants. Child Adolesc Psychiatric Clin North Am 4(1):123-168
- Paxinos G, Watson C (1986): The Rat Brain in Stereotaxic Coordinates, 2nd ed. San Diego, Academic Press
- Zametkin AJ, Rapoport JL (1987): Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review. In Meltzer HY (ed), Psychopharmacology: the Third Generation of Progress. New York, Raven Press, pp 837-847
Cited by
Sorted by citations
Inhibition and impulsivity: behavioral and neural basis of response control
Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592
sagvolden, T., johansen, E. B., aase, H., & russell, V. A. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000075 · Cited by 1,035
The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics
Sonuga-Barke, E. J. S. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.08.005 · Cited by 816
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617
Neurophysiology of performance monitoring and adaptive behavior
Ullsperger, M., Danielmeier, C., & Jocham, G. (2014) · Physiological Reviews · doi:10.1152/physrev.00041.2012 · Cited by 634
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573
Eagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks
Arnsten, A. F. T. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.027 · Cited by 493
Tripp, G., & Wickens, J. R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.026 · Cited by 492
Stimulants: Therapeutic Actions in ADHD
Arnsten, A. F. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301164 · Cited by 473
Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry
Dalley, J. W., Mar, A. C., Economidou, D., & Robbins, T. W. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.021 · Cited by 467
Halperin, J. M., & Schulz, K. P. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.4.560 · Cited by 446
Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J. L., Narendran, R., Gil, R., Hackett, E., Girgis, R., Ojeil, N., Moore, H., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2414 · Cited by 398
The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder
Madras, B. K., Miller, G. M., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.011 · Cited by 393
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Arnsten, A. F. T., & Pliszka, S. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.020 · Cited by 383
Arnsten, A. F. T. (2009) · CNS Drugs · doi:10.2165/00023210-200923000-00005 · Cited by 371
Arnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359
Luman, M., Tripp, G., & Scheres, A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.021 · Cited by 335
The many faces of fatigue in major depressive disorder
Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004729 · Cited by 288
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder
Chamberlain, S. R., del Campo, N., Dowson, J., Müller, U., Clark, L., Robbins, T. W., & Sahakian, B. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.003 · Cited by 288
The neuropsychopharmacology of attention-deficit/hyperactivity disorder
Pliszka, S. R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.026 · Cited by 276
Wilens, T. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318173312f · Cited by 269
Nutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259
McGaughy, J., Ross, R. S., & Eichenbaum, H. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.064 · Cited by 226
Gamo, N. J., Wang, M., & Arnsten, A. F. T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.06.015 · Cited by 232
Frank, M. J., Santamaria, A., O'Reilly, R. C., & Willcutt, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301278 · Cited by 227
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W., Winner, P. K., Dunn, D. W., Dure, L. S., Sallee, F. R., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000188869.58300.a7 · Cited by 225
ADHD and the Prefrontal Cortex
Arnsten, A. F. T. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.01.018 · Cited by 220
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
Bari, A., Eagle, D. M., Mar, A. C., Robinson, E. S. J., & Robbins, T. W. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1537-0 · Cited by 194
Prefrontal and monoaminergic contributions to stop-signal task performance in rats
Bari, A., Mar, A. C., Theobald, D. E., Elands, S. A., Oganya, K. C. N. A., Eagle, D. M., & Robbins, T. W. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1543-11.2011 · Cited by 188
Navarra, R., Graf, R., Huang, Y., Logue, S., Comery, T., Hughes, Z., & Day, M. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.06.017 · Cited by 183
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185
Rubia, K., Halari, R., Cubillo, A., Smith, A. B., Mohammad, A.-M., Brammer, M., & Taylor, E. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.30 · Cited by 184
Non?stimulant medications in the treatment of ADHD
Banaschewski, T., Roessner, V., Dittmann, R. W., Janardhanan Santosh, P., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1010-x · Cited by 183
Burghardt, N. S., Bush, D. E. A., McEwen, B. S., & LeDoux, J. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.023 · Cited by 179
Morphological Abnormalities of the Thalamus in Youths With Attention Deficit Hyperactivity Disorder
Ivanov, I., Bansal, R., Hao, X., Zhu, H., Kellendonk, C., Miller, L., Sanchez-Pena, J., Miller, A. M., Chakravarty, M. M., Klahr, K., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030398 · Cited by 172
Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174
Rubia, K., Halari, R., Mohammad, A.-M., Taylor, E., & Brammer, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.018 · Cited by 171
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder
Corona, J. C. (2020) · Antioxidants · doi:10.3390/antiox9111039 · Cited by 163
The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex
Spencer, R. C., Devilbiss, D. M., & Berridge, C. W. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.013 · Cited by 164
Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine
BANGS, M. E., TAUSCHER-WISNIEWSKI, S., POLZER, J., ZHANG, S., ACHARYA, N., DESAIAH, D., TRZEPACZ, P. T., & ALLEN, A. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815d88b2 · Cited by 152
KRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000222788.34229.68 · Cited by 150
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
O'Sullivan, J. B., Ryan, K. M., Curtin, N. M., Harkin, A., & Connor, T. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570800967x · Cited by 146
Newman, L. A., Darling, J., & McGaughy, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1097-8 · Cited by 137
Fernando, A. B. P., Economidou, D., Theobald, D. E., Zou, M.-F., Newman, A. H., Spoelder, M., Caprioli, D., Moreno, M., Hipόlito, L., Aspinall, A. T., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2408-z · Cited by 135
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Cubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M. J., Simmons, A., & Rubia, K. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs296 · Cited by 116
Catecholaminergic Regulation of Learning Rate in a Dynamic Environment
Jepma, M., Murphy, P. R., Nassar, M. R., Rangel-Gomez, M., Meeter, M., & Nieuwenhuis, S. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005171 · Cited by 91
Schulz, K. P., Fan, J., Bédard, A.-C. V., Clerkin, S. M., Ivanov, I., Tang, C. Y., Halperin, J. M., & Newcorn, J. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2053 · Cited by 114
SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder
Krause, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.611 · Cited by 110
A Comprehensive In Vitro Screening of d-, l- , and dl-threo -Methylphenidate: An Exploratory Study
Markowitz, J. S., DeVane, C. L., Pestreich, L. K., Patrick, K. S., & Muniz, R. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.687 · Cited by 109
Kenemans, J. L., & Kähkönen, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.157 · Cited by 104
Bari, A., & Robbins, T. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3141-6 · Cited by 105
Agmatine rescues autistic behaviors in the valproic acid-induced animal model of autism
Kim, J.-W., Seung, H., Kim, K. C., Gonzales, E. L. T., Oh, H. A., Yang, S. M., Ko, M. J., Han, S.-H., Banerjee, S., & Shin, C. Y. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.014 · Cited by 102
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
Spencer, T. J., Sallee, F. R., Gilbert, D. L., Dunn, D. W., McCracken, J. T., Coffey, B. J., Budman, C. L., Ricardi, R. K., Leonard, H. L., Allen, A. J., et al. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707306109 · Cited by 98
Gilbert, D. L., Ridel, K. R., Sallee, F. R., Zhang, J., Lipps, T. D., & Wassermann, E. M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300806 · Cited by 97
Methylphenidate and cocaine: the same effects on gene regulation?
YANO, M., & STEINER, H. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.004 · Cited by 94
Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s256586 · Cited by 96
Gau, S. S.-F., & Shang, C.-Y. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990836 · Cited by 91
Bondi, C. O., Jett, J. D., & Morilak, D. A. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.016 · Cited by 88
Cubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2014) · Psychological Medicine · doi:10.1017/s0033291713000676 · Cited by 88
Abuse liability assessment of atomoxetine in a drug-abusing population
Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M., & Allen, A. J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.008 · Cited by 87
Wang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84
Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood
Nemoda, Z., Szekely, A., & Sasvari-Szekely, M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.002 · Cited by 78
The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining
Gonon, F. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.09.010 · Cited by 79
Yamashita, M., Fukushima, S., Shen, H.-W., Hall, F. S., Uhl, G. R., Numachi, Y., Kobayashi, H., & Sora, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301009 · Cited by 77
Central Nervous System Biogenic Amine Targets for Control of Appetite and Energy Expenditure
Nelson, D. L., & Gehlert, D. R. (2006) · Endocrine · doi:10.1385/endo:29:1:49 · Cited by 78
Neurochemical Enhancement of Conscious Error Awareness
Hester, R., Nandam, L. S., O'Connell, R. G., Wagner, J., Strudwick, M., Nathan, P. J., Mattingley, J. B., & Bellgrove, M. A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4052-11.2012 · Cited by 68
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3473 · Cited by 70
Hepatic Events Associated with Atomoxetine Treatment for??Attention-Deficit??Hyperactivity Disorder
Bangs, M. E., Jin, L., Zhang, S., Desaiah, D., Allen, A. J., Read, H. A., Regev, A., & Wernicke, J. F. (2008) · Drug Safety · doi:10.2165/00002018-200831040-00008 · Cited by 68
Vanicek, T., Spies, M., Rami-Mark, C., Savli, M., Höflich, A., Kranz, G. S., Hahn, A., Kutzelnigg, A., Traub-Weidinger, T., Mitterhauser, M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1226 · Cited by 61
Methylphenidate Effects on Prefrontal Functioning During Attentional-Capture and Response Inhibition
Pauls, A. M., O'Daly, O. G., Rubia, K., Riedel, W. J., Williams, S. C. R., & Mehta, M. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.028 · Cited by 57
Farr, O. M., Zhang, S., Hu, S., Matuskey, D., Abdelghany, O., Malison, R. T., & Li, C.-S. R. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000674 · Cited by 57
Atomoxetine facilitates attentional set shifting in adolescent rats
Cain, R. E., Wasserman, M. C., Waterhouse, B. D., & McGaughy, J. A. (2011) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2011.04.003 · Cited by 55
Jenson, D., Yang, K., Acevedo-Rodriguez, A., Levine, A., Broussard, J. I., Tang, J., & Dani, J. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.029 · Cited by 52
Alkam, T., Mamiya, T., Kimura, N., Yoshida, A., Kihara, D., Tsunoda, Y., Aoyama, Y., Hiramatsu, M., Kim, H.-C., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4591-z · Cited by 50
Effects of α-2A adrenergic receptor agonist on time and risk preference in primates
Kim, S., Bobeica, I., Gamo, N. J., Arnsten, A. F. T., & Lee, D. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2520-0 · Cited by 47
Baird, A. L., Coogan, A. N., Kaufling, J., Barrot, M., & Thome, J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.038 · Cited by 46
Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review
Ghanizadeh, A. (2013) · Journal of Attention Disorders · doi:10.1177/1087054712443154 · Cited by 43
Zhang, C.-L., Feng, Z.-J., Liu, Y., Ji, X.-H., Peng, J.-Y., Zhang, X.-H., Zhen, X.-C., & Li, B.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051910 · Cited by 41
Wilson, C. A., Schade, R., & Terry, A. V. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.040 · Cited by 40
Are Eating Disorders Related to Attention Deficit/Hyperactivity Disorder?
Reinblatt, S. P. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0060-7 · Cited by 39
Jordan, C. J., Harvey, R. C., Baskin, B. B., Dwoskin, L. P., & Kantak, K. M. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.04.020 · Cited by 38
Brenhouse, H. C., Dumais, K., & Andersen, S. L. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.063 · Cited by 38
Isfandnia, F., El Masri, S., Radua, J., & Rubia, K. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105703 · Cited by 36
Arabgol, F., Panaghi, L., & Hebrani, P. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-008-0705-9 · Cited by 33
Metadata
- Authors
- Bymaster, F.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Bymaster, F
- Venue
- Neuropsychopharmacology
- Published
- 2002-11
- Volume
- 27
- Issue
- 5
- Pages
- 699-711
- ISSN
- 0893-133X (ISSN-L)
- OpenAlex
- W2057760214
- Cited by
- 1,123
- References
- 7
- Citations by year
- 2026: 25 · 2025: 31 · 2024: 52 · 2023: 47 · 2022: 35 · 2021: 44 · 2020: 40 · 2019: 41 · 2018: 24 · 2017: 49 · 2016: 65 · 2015: 64 · 2014: 77 · 2013: 57 · 2012: 66
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, norepinephrine transporter, dopamine transporter, serotonin transporter, prefrontal cortex, Fos expression, methylphenidate, monoamine transporters, drug selectivity, striatum, nucleus accumbens, drug abuse liability
- MeSH terms
- Atomoxetine Hydrochloride, Animals, Attention Deficit Disorder with Hyperactivity, Dopamine, Drug Synergism, Humans, Male, Norepinephrine, Propylamines, Rats, Sprague-Dawley, Prefrontal Cortex, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
